SamaCare vs Silna Health
Two Prior Authorization vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| SamaCare | Silna Health | |
|---|---|---|
| Pricing model | Free to providers (funded by payers/pharma) · Pharma funds premium services and data | Not published · Quote-based |
| Speed to go live | Web portal, no IT project required | Share data files; Silna handles setup |
| Automation model | Software platform · Unified PA portal, AI touchless tier | Autonomous agents · AI runs benefit checks and auths |
| Built for | Small practices, Mid-size groups | Small practices, Mid-size groups |
| Security posture | SOC 2 Type I, HIPAA | SOC 2 Type II, HIPAA |
| Company maturity | 8 yrs (est. 2018) | 3 yrs (est. 2023) |
| Financial backing | $33M+ · Series B | $27M · Series A |
| Named customers | None public | None public |
| Published results | No public numbers | Specific numbers public |
| Documented integrations | 4 listed | None documented |
| Third-party validation | None found | None found |
Bottom line
- Pick SamaCare if you are a specialty practice buried in medical-benefit prior auths and want one free web portal replacing faxes and payer portals today.
- Pick Silna if you run a therapy or specialty practice (ABA, PT/OT, behavioral) and want benefit checks and prior auths done for you within weeks of signing.
SamaCare
Prior authorization platform for buy-and-bill specialty drugs
- Founded
- 2018
- HQ
- San Francisco, CA
- Stage
- Series B
- Raised
- $33M+
What it does
- One portal for all medical benefit PA submissions
- AI-assisted form completion and payer requirements
- Status tracking, renewals, and expiration alerts
- Benefit verification and enrollment workflows
- Approval analytics across a 20K-provider network
Where it's strong
- Purpose-built for buy-and-bill drugs, a workflow retail-focused PA tools handle poorly.
- Free for practices because pharma funds it, which removes the budget fight.
- Network data from roughly 20,000 providers improves payer form accuracy and approval odds.
What buyers should weigh
- The pharma-funded model means manufacturers see aggregate data; understand the data terms before signing.
- Scope is medication PA for specialty drugs, not procedures, imaging, or surgical auths.
- Smaller company (Series B) than incumbent networks, so vendor risk is higher than with McKesson or Optum.
Integrations
Silna Health
Prior auth and benefits automation for therapy providers
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series A
- Raised
- $27M
What it does
- Automates benefit checks and eligibility verification before visits
- Prepares, submits, and tracks prior authorization requests
- Monitors authorizations and flags expirations and renewals
- Covers 1,000+ payers across all 50 states
- Sits alongside existing EHR and practice management systems
- Built for ABA, PT/OT, speech, psychiatry, and other therapy specialties
Where it's strong
- Purpose-built for therapy and specialty providers like ABA, where prior auth volume is the core operational pain.
- Fast deployment because it sits alongside your stack rather than requiring deep EHR integration.
- Strong reported results: insurance verification cut from 30 minutes to 30 seconds and approvals in hours with a claimed 99.8% success rate.
What buyers should weigh
- Young company (founded 2023) with a short track record and no large publicly named customers.
- Narrow front-end focus: it handles benefits and auth, not claims, denials, or the rest of the revenue cycle.
- The no-integration approach means data lives in a separate staff-facing tool rather than flowing into your EHR automatically.
Compare against the rest of Prior Authorization
Deciding between these two?
First Pass tracks Prior Authorization every week: funding, launches, and what changed since this page was written.